Ayla Ellison

Consumer wearables are popular for a reason. People like to have their health data on demand. These insights can encourage healthy habits and may flag early signals of an underlying illness.

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different.

The U.S. is facing a rapidly aging population alongside a dearth of primary care physicians, who play a crucial role in catching health issues early and keeping costs low.

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthc

A genome can be sequenced in days. Medicines are being built around molecular targets the industry wrote off as unreachable a decade ago. Software finds patterns in clinical data no human reader would catch. Researchers are intervening in disease at its genetic source. And yet patients still wait years for a diagnosis. Hospital bills remain indecipherable. Millions of people live too far from a doctor to see one regularly.

Some breakthroughs arrive with an FDA approval. Others show up earlier, when a long-stubborn scientific problem finally starts to give way.This year’s Fierce 50 Breakthrough honorees span that spectrum.

The 2026 Fierce 50 brings together scientists, physicians, public health leaders, patient advocates and organizations working in very different ways to move healthcare and the life sciences forward.

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from de

Video games are a massive industry, and they're successful because they have mastered the art of player engagement. What if you could apply those same tactics to engage doctors?

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer.